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43%) end point costs. CONCLUSIONS: Statin exposure signiﬁ cantly reduced the
risk of recurrent asthma-related hospitalization/ER events and associated costs over
12 months in this analysis of ICS-treated adult asthmatic patients.
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OBJECTIVES: There is an attribution of smoking morbidity about 30% relate to lung
cancer (LC), about 20% relate to cardiovascular diseases (CVD) eg. myocardial infarc-
tion (MI) and stroke and about 75% of patients with chronic obstructive pulmonary 
disease (COPD). The main objective of this study was to determine direct medical 
costs related to smoking in Slovakia and the deﬁ ned costs of smoking cessation.
METHODS: Direct medical costs were evaluated from data collected in 2007 from 
the General Health Insurance Company, the largest one in Slovakia, covering 55% of 
all 5,400,000 inhabitants. The results were recalculated to the whole population. The 
costs were quoted in 2007 prices. RESULTS: The smoking costs of those patients 
treated on LC were €19,726,950; on COPD they were €19,454,040; on stroke they
were €6,019,778 and on MI they were €26,247,289. It was 33.66% from total direct
costs €212,243,357 assigned to these diseases and 2.15 % of total Slovakia health
care budget. The cost of treating a smoker on diseases associated with smoking was 
€1,114. Decreasing the number of smokers by 10% will reduce health care costs by
€7,144,806 per year, i.e. 0.22% from total budget. The cost of treatment to stop 
smoking using varenicline was €919 per patient. CONCLUSIONS: The direct costs
associated with smoking comprise an important part of total health care budget in
Slovakia. They signalize the need to establish effective strategies for smoking cessation. 
44% clinical effectiveness of varenicline shows to be a cost-effective way in reducting 
smoking and decreasing health care expenditures.
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OBJECTIVES: Omalizumab (Xolair) is an FDA-approved immunomodulator for the 
treatment of steroid refractory, uncontrolled (symptomatic), moderate-severe persis-
tent asthma in patients 12 years of age with a positive skin test to a perennial aeroal-
lergen. Our objective was to estimate the budget impact of omalizumab availability 
on a hypothetical health plan (US payer perspective). METHODS: The budget impact
was estimated as the difference in two scenarios where omalizumab is used by moder-
ate-severe uncontrolled asthmatics with a conﬁ rmed allergic component over similar 
controlled asthma patients on standard of care. Publicly available, real-world utiliza-
tion data were used to develop percentage estimates for omalizumab-eligible patients 
hierarchically as follows: treated asthmatics in the approved age-groups who exhibited
poor symptom control (55% of patients) and were moderate-severe asthmatics (40%) 
with IgE mediated asthma (60%) and whose IgE levels were within the approved
range per the omalizumab package insert (61%) were included in the model. Of these, 
based on real world utilization data, 3.2% would receive omalizumab therapy. Omali-
zumab-related costs in the model consisted of eligibility screening, drug, and ofﬁ ce
administration. Health service costs impacted by omalizumab consisted of unsched-
uled asthma-related exacerbation ofﬁ ce visits, emergency room visits, and hospitaliza-
tions. The impact of key model parameters on the budget was assessed in sensitivity 
analyses (SA). RESULTS: The incremental cost of omalizumab-treated patients 
was estimated at $1285 per omalizumab user per month or $0.11 per member per 
month (PMPM) given the additive costs of omalizumab screening, drug and adminis-
tration. When parameters were varied / 10% in a one-way sensitivity analysis, the
PMPM varied within $0.10 to $0.125. Results were most sensitive to the estimated
percentage of patients on omalizumab. CONCLUSIONS: The model demonstrated
that omalizumab availability resulted in an incremental cost of $0.11 PMPM. System-
atic variation of the model parameters by / 10% in the SA resulted in a PMPM 
range of $0.10–$0.125.
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OBJECTIVES: Cigarette smoking imposes a signiﬁ cant burden on employers as a 
consequence of increased absenteeism and smoking-related breaks during the working 
day. Despite the evidence supporting the efﬁ cacy and cost-effectiveness of smoking 
cessation treatments (SCTs), relatively few private drug plans reimburse such treat-
ments. The objectives of this study were to calculate the projected budget impact 
and return on investment for an employer funded drug plan in Canada in the ﬁ rst 3 
years of introducing SCT coverage. METHODS: A recently published state-transition 
model reﬂ ecting relevant smoking statuses was used for the analyses. The model 
involves a comparison of the clinical and economic outcomes for a hypothetical cohort
of 10,000 Canadian workers followed for three years. The relative efﬁ cacy of various
smoking cessation strategies (varenicline, bupropion, nicotine replacement therapy
and unaided cessation) were taken from the literature. Canadian data were used to
determine the population of smokers, marketplace dynamics, SCT costs, smoking-
related absenteeism and lost productivity. One-way sensitivity analyses were per-
formed. RESULTS: The analysis lead to an estimate of 1,801 employees who were
smokers at baseline. An estimated incremental total of 79 smokers would successfully 
quit smoking by the end of the 3-year time horizon with a SCT reimbursement 
program compared with a no coverage scenario. Budget impact associated with the
SCT coverage scenario equated to $164,182 while projected savings to employers were 
estimated at $381,292 over 3 years. This represented projected net savings to employ-
ers of $217,110 and a return on investment of $2.32 for every dollar spent to support 
a SCT reimbursement program. One-way sensitivity analyses conﬁ rmed the robustness 
of the ﬁ ndings. CONCLUSIONS: For a relatively modest investment, a SCT reim-
bursement program in the Canadian workplace is likely to reduce the number of 
smokers in the workforce, while generating a positive return on investment for 
employers within a short timescale.
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OBJECTIVES: To estimate the costs and beneﬁ ts of Timing Pharmaceutical
Intervention (TPI) through an example of asthma in Alberta, Canada. METHODS:
We included changes in direct health care and lost productivity costs, and Health
Related Quality of Life (HRQOL) among Alberta’s asthmatic adults (18 years
and over) in a one year time period. Health care costs and beneﬁ ts were estimated
through the effects of TPI on drug uses and health care utilization patterns, including 
hospital days, ER visits and physician visits. Productivity and HRQOL beneﬁ ts 
were estimated through the effects of TPI on the number of symptom free days 
(SFDs) of patients at age 18–64 and at all adult ages respectively. Health care
utilization rates, unit costs, SFDs days and HRQOL index scores from the literature
were used for analyses. The costs were adjusted to 2006 Canadian dollar value. 
RESULTS: In a year, in addition to a saving of $0.2–$0.3 million in health care 
costs, TPI on asthma generates a beneﬁ t of $12–$19 million in terms of improved
productivity and 22–29 quality adjusted life years in terms of improved HLQOL. 
CONCLUSIONS: The costing model provides us with a rough indication of the eco-
nomic impact of TPI. It is not expected that TPI will always yield net savings in terms 
of health care costs for all chronic conditions. This will depend on speciﬁ c diseases 
and the cost effectiveness of the intervention among the target population. However, 
other beneﬁ ts, such as improved HRQOL and productivity, should be considered in 
the decision making.
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OBJECTIVES: To compare the health care costs of children with newly-diagnosed
allergic rhinitis (AR) who subsequently received allergy immunotherapy (IT) to a
matched group of children with newly-diagnosed AR who did not receive IT. 
METHODS: We examined 10 years (1997–2007) of Florida Medicaid paid claims 
to identify children (18 years) newly diagnosed with AR who received IT and 
had at least 18 months of data following IT initiation (IT Group). Patients
were matched (by age at AR diagnosis, sex, race, and presence of asthma, atopic 
dermatitis, or conjunctivitis) over the same period to newly AR-diagnosed children 
who did not subsequently receive IT (Control Group). Wilcoxon signed-rank tests
compared 2-year, median, per-patient total health care costs (pharmacy costs 
inpatient costs  outpatient costs  IT costs if any) at 3, 6, 12, and 18 months.
RESULTS: Among 3,240,046 Florida Medicaid-enrolled children, 196,687 (6%) 
were newly diagnosed with AR, and 3,931 (2%) subsequently received IT. A subset 
(N  2,291) had at least 18 months of follow-up data and were matched to one or 
more of 71,790 controls. Within three months of IT initiation, the IT Group incurred
signiﬁ cantly lower total health care costs ($1,006 vs. $1,365, p  0.0001) than the 
matched Control Group. Signiﬁ cant cost savings were maintained across 6 months 
($1,810 vs. $2,474, p  0.0001), 12 months ($3,242 vs. $4,519, p  0.0001), and 
18 months ($4,329 vs. $6,138, p  0.0001), growing from $359 at 3 months to $1,809
at 18 months. In contrast, the 3-, 6-, 12-, and 18-month per-patient median cost
of IT was $250, $360, $488, and $565, respectively. CONCLUSIONS: This is the 
ﬁ rst U.S.-based study to report signiﬁ cant health care cost savings for IT among
AR-diagnosed children. Findings suggest that these savings may occur within a few 
months of treatment initiation, appear to increase over time, and may more than offset
the cost of IT.
